PASTEUR MERIEUX CONNAUGHT VACCINE SALES GROW 41% IN U.S. DURING 1997; MERCK VACCINES UP 27.5%: COZAAR, CRIXIVAN AND FOSAMAX COMBINE FOR $1 BIL. IN U.S.
Pasteur Merieux Connaught vaccine sales in the U.S. increased by 41% during 1997 on the strength of Tripedia (pertussis, diphtheria, tetanus) and Ipol (injectable polio), Rhone-Poulenc said Jan. 29.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth